• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Akoustis Soars 200% in Pre-Market Amid Bankruptcy Fears After $39M Lawsuit Loss To Qorvo

    5/22/24 7:05:11 AM ET
    $AKTS
    $QRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Semiconductors
    Technology
    Get the next $AKTS alert in real time by email

    Akoustis Technologies (NASDAQ:AKTS) was trading nearly 200% higher during the Wednesday pre-market session as the company floated the probability of bankruptcy after losing a lawsuit against semiconductor manufacturer Qorvo Inc. (NASDAQ:QRVO).

    What Happened: At the time of writing, Akoustis was trading 200.6% higher at $0.41 on the Wednesday pre-market, according to Benzinga Pro. This comes after it closed at $0.13 on Tuesday.

    Akoustis recently lost a lawsuit against Qorvo in the District Court for the District of Delaware. As part of the lawsuit, Acoustis needs to pay $38.6 million, which the company says affects its ability to raise capital and continue operations.

    Why It Matters: Akoustis, which manufactures bulk acoustic wave radio frequency (RF) filters, was found to have willfully misappropriated Qorvo trade secrets and infringed on two Qorvo patents.

    The company said that the lawsuit’s verdict might also lead them to consider bankruptcy protection.

    The lawsuit verdict also comes on the heels of its third-quarter revenue for the fiscal year ending in 2024. As reported on May 13, the revenue was up by 7% quarter-over-quarter to $7.5 million. The growth was attributed to robust activity in the sales and design win pipelines, semiconductor services business, and new products introduced in Wi-Fi 6E/7 and 5G infrastructure. The Company had expressed revenue expectations between $7.0 to $7.5 million in sales revenue in the June quarter.

    Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

    Image via Shutterstock

    Get the next $AKTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTS
    $QRVO

    CompanyDatePrice TargetRatingAnalyst
    Qorvo Inc.
    $QRVO
    4/20/2026$66.00Neutral → Underperform
    Mizuho
    Qorvo Inc.
    $QRVO
    4/17/2026Outperform → Peer Perform
    Wolfe Research
    Aktis Oncology Inc.
    $AKTS
    3/9/2026$30.00Buy
    H.C. Wainwright
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$30.00Overweight
    Analyst
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$34.00Buy
    BofA Securities
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$31.00Outperform
    Leerink Partners
    Aktis Oncology Inc.
    $AKTS
    2/3/2026Buy
    TD Cowen
    Qorvo Inc.
    $QRVO
    1/28/2026$110.00 → $95.00Buy
    Craig Hallum
    More analyst ratings

    $AKTS
    $QRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:17:54 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $QRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Qorvo downgraded by Mizuho with a new price target

    Mizuho downgraded Qorvo from Neutral to Underperform and set a new price target of $66.00

    4/20/26 8:24:56 AM ET
    $QRVO
    Semiconductors
    Technology

    Qorvo downgraded by Wolfe Research

    Wolfe Research downgraded Qorvo from Outperform to Peer Perform

    4/17/26 8:09:01 AM ET
    $QRVO
    Semiconductors
    Technology

    H.C. Wainwright initiated coverage on Aktis Oncology with a new price target

    H.C. Wainwright initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $30.00

    3/9/26 9:06:39 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $QRVO
    SEC Filings

    View All

    SEC Form 8-K filed by Aktis Oncology Inc.

    8-K - Aktis Oncology, Inc. (0002035832) (Filer)

    4/16/26 4:01:24 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Aktis Oncology Inc.

    10-K - Aktis Oncology, Inc. (0002035832) (Filer)

    3/30/26 5:29:03 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Qorvo Inc.

    SCHEDULE 13G/A - Qorvo, Inc. (0001604778) (Subject)

    3/27/26 11:36:55 AM ET
    $QRVO
    Semiconductors
    Technology

    $AKTS
    $QRVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

    BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company's newly established Science and Technology Committee of the Board of Directors. "We are delighted to welcome Glenn to our Board as we continue to make significant progress toward upcoming clinical and corporate milestones," said Matthew Roden, PhD, President a

    4/16/26 8:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

    Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial

    3/30/26 4:01:00 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NexSat Space Systems Launches and Unveils ACE: The Invisible Antenna

    Revolutionary Ku/Ka Fully Integrated Aero-Conformal Antenna System Sets a New Standard for Aircraft Connectivity and Paves the Way for Supersonic and Hypersonic Flight — Developed in Collaboration with Qorvo ATLANTA, March 23, 2026 (GLOBE NEWSWIRE) -- NexSat Space Systems Corporation (NexSat) today announced its official company launch and unveiled its first groundbreaking product development, ACE (Aero Conformal ESA) — an industry-first fully integrated Ku/Ka-band electronically steered antenna (ESA), known as "The Invisible Antenna." "With NexSat's launch, we're on a mission to rewrite the antenna rulebook with our Aero Conformal Electronically Scanned Array (A.C.E.), bringing a smartp

    3/23/26 10:10:42 AM ET
    $QRVO
    Semiconductors
    Technology

    $AKTS
    $QRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gormley Glenn

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    4/16/26 4:15:09 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Gormley Glenn

    3 - Aktis Oncology, Inc. (0002035832) (Issuer)

    4/16/26 4:05:08 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harding John R sold $99,192 worth of shares (1,200 units at $82.66), decreasing direct ownership by 13% to 7,990 units (SEC Form 4)

    4 - Qorvo, Inc. (0001604778) (Issuer)

    2/27/26 4:07:54 PM ET
    $QRVO
    Semiconductors
    Technology

    $AKTS
    $QRVO
    Leadership Updates

    Live Leadership Updates

    View All

    Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

    BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company's newly established Science and Technology Committee of the Board of Directors. "We are delighted to welcome Glenn to our Board as we continue to make significant progress toward upcoming clinical and corporate milestones," said Matthew Roden, PhD, President a

    4/16/26 8:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qorvo® Announces Results of Board Refreshment Process

    Appoints Richard L. Clemmer and Christopher R. Koopmans as Independent Directors David H. Y. Ho to Retire from the Board GREENSBORO, N.C., April 14, 2025 (GLOBE NEWSWIRE) -- Qorvo® (NASDAQ:QRVO), a leading global provider of connectivity and power solutions, today announced the appointment of Messrs. Richard L. Clemmer and Christopher R. Koopmans as new independent members of its Board of Directors, effective immediately. Additionally, the Company announced that David H. Y. Ho, who was not standing for reelection at the Company's 2025 Annual Meeting of Stockholders, will retire from the Board, effective immediately. Today's announcement is the result of an important ref

    4/14/25 7:30:16 AM ET
    $QRVO
    Semiconductors
    Technology

    Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/6/24 6:29:00 PM ET
    $AMTM
    $APO
    $CMA
    Real Estate
    Investment Managers
    Finance
    Major Banks

    $AKTS
    $QRVO
    Financials

    Live finance-specific insights

    View All

    Qorvo® Announces Fiscal 2026 Third Quarter Financial Results

    GREENSBORO, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Qorvo® (NASDAQ:QRVO), a leading global provider of connectivity and power solutions, today announced financial results for the Company's fiscal 2026 third quarter ended December 27, 2025. On a GAAP basis, revenue for Qorvo's fiscal 2026 third quarter was $993.0 million, gross margin was 46.7%, operating income was $192.1 million, and diluted earnings per share was $1.75. On a non-GAAP basis, gross margin was 49.1%, operating income was $247.6 million, and diluted earnings per share was $2.17. Bob Bruggeworth, president and chief executive officer of Qorvo, said, "Qorvo's December quarterly revenue primarily reflects strength at our larg

    1/27/26 4:00:00 PM ET
    $QRVO
    Semiconductors
    Technology

    Qorvo® to Webcast Quarterly Earnings Conference Call on January 27, 2026

    GREENSBORO, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Qorvo® (NASDAQ:QRVO), a leading global provider of connectivity and power solutions, will host a conference call to review fiscal 2026 third quarter financial results on Tuesday, January 27, 2026, at 4:30 p.m. (ET). The conference call will be webcast live on the Company's Investor Relations website at the following URL: https://ir.qorvo.com (under "Events & Presentations"). A telephone playback of the conference call will be available approximately two hours after the call's completion and can be accessed by dialing 1-412-317-0088 and using the passcode 7930075. The playback will be available through the close of business on February 3,

    1/13/26 8:00:00 AM ET
    $QRVO
    Semiconductors
    Technology

    Qorvo® Announces Fiscal 2026 Second Quarter Financial Results

    GREENSBORO, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Qorvo® (NASDAQ:QRVO), a leading global provider of connectivity and power solutions, today announced financial results for the Company's fiscal 2026 second quarter ended September 27, 2025. On a GAAP basis, revenue for Qorvo's fiscal 2026 second quarter was $1.1 billion, gross margin was 47.0%, operating income was $157.7 million, and diluted earnings per share was $1.28. On a non-GAAP basis, gross margin was 49.7%, operating income was $252.6 million, and diluted earnings per share was $2.22. Bob Bruggeworth, president and chief executive officer of Qorvo, said, "In the September quarter, ACG supported our largest customer's smartphone

    11/3/25 4:00:00 PM ET
    $QRVO
    Semiconductors
    Technology

    $AKTS
    $QRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akoustis Technologies Inc.

    SC 13G/A - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/12/24 1:34:05 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/4/24 11:00:32 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Qorvo Inc.

    SC 13G/A - Qorvo, Inc. (0001604778) (Subject)

    7/8/24 4:32:39 PM ET
    $QRVO
    Semiconductors
    Technology